Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Hisataka Yasuda, Nobuyuki Shima, N. Nakagawa et al. · Proceedings of the National Academy of Sciences · 1998 · 4.2K citations · Full text

Osteoprotegerin/osteoclastogenesis-inhibitory Factor, Sclerostin, Tumor Microenvironment +14

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

Young‐Yun Kong, Hiroki Yoshida, Ildiko Sarosi et al. · Nature · 1999 · 3.3K citations

Developmental Biology, Key Regulator, Bone Morphogenic Protein +11

Stimulation of Bone Formation in Vitro and in Rodents by Statins

Gregory R. Mundy, R.J. Burriss Garrett, S. E. Harris et al. · Science · 1999 · 1.8K citations

Osteoclast-Like Cell Formation and its Regulation by Osteotropic Hormones in Mouse Bone Marrow Cultures*

Naoyuki Takahashi, Hiromi Yamana, Shusaku Yoshiki et al. · Endocrinology · 1988 · 734 citations

Cathepsin K, but Not Cathepsins B, L, or S, Is Abundantly Expressed in Human Osteoclasts

Fred H. Drake, Robert A. Dodds, Ian E. James et al. · Journal of Biological Chemistry · 1996 · 711 citations · Full text